{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457121609
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = [[hepatitis B]] surface antigen
<!-- Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 569658-80-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| C=6416 | H=9924 | N=1732 | O=1982 | S=44
| molecular_weight =  
}}

'''Exbivirumab''' is a [[human]] [[monoclonal antibody]]<ref>[http://whqlibdoc.who.int/druginfo/INN_2005_list53.pdf WHO Drug Information]</ref> developed for the treatment of [[hepatitis B]] infections.<ref>{{cite journal|last=Shouval|first=D|year=2006|title=Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatits B Virus (Hbv) in Liver Transplant (Lt) Recipients|journal=Hepatology|volume=44|issue=4|doi=10.1002/hep.21395 |pmid=17001593|pages=188Aâ€“700A [196A]|display-authors=etal}}</ref>

==References==
{{reflist}}

{{Monoclonals for infectious disease and toxins}}

[[Category:Monoclonal antibodies]]
[[Category:Experimental drugs]]


{{antiinfective-drug-stub}}
{{monoclonal-antibody-stub}}